Tumor immunotherapy generally refers to PD-1 (programmed death receptor-1), PD-L1 (programmed death ligand-1) immunotherapy. PD-1 is a receptor expressed on the surface of T-cells that binds to the ligands PD-L1/PD-L2 in tumor cells, thus blocking the immune effects of T-cells. The PD-1 monoclonal antibodies commonly used in the clinic at present include pembrolizumab, navumab, etc., which are mainly used for the treatment of PD-L1-expressing metastatic non-small cell lung cancer, unresectable or metastatic melanoma, breast cancer, etc. The efficacy of immunotherapy needs more clinical research, and regular review is needed during treatment to prevent adverse reactions. Please strictly follow the doctor’s prescription for medication and do not use medication on your own.